MYC and neoplasm: The nonsteroidal anti-inflammatory drug (NSAID) diclofenac negatively affects tumor growth in vitro and in vivo primarily by its inhibitory effect on Cyclooxygenases COX1 and COX2 [1], and also by COX-independent effects associated with a reduced c-MYC expression causing a decreased glucose uptake, lactate production and glutaminolysis [2–4].